Albertsen BK, et al. - Given that, in childhood acute lymphoblastic leukemia (ALL) therapy, asparaginase is a vital drug frequently given for months to obtain continuous asparagine depletion, researchers randomly assigned patients to continuous vs intermittent pegylated-asparaginase (PEG-asp) treatment to investigate if there would be decreased toxicity with unchanged effectiveness. Five intramuscular PEG-asp injections (1,000 IU/m²) every two weeks were provided to children (median age, 4.2 years) treated for non–high-risk ALL according to the Nordic Society for Pediatric Hematology and Oncology ALL2008 protocol. Then these children were randomly assigned to additional three doses (6-week intervals [experimental arm], n=309) vs 10 doses (2-week intervals [standard arm], n=316). Outcomes revealed excellent cure rates and reduced toxicity risk with the use of intermittent PEG-asp therapy thereby supporting its use after the first 10 weeks in future childhood ALL trials that apply prolonged PEG-asp therapy.